0001127602-20-029315.txt : 20201117 0001127602-20-029315.hdr.sgml : 20201117 20201117165848 ACCESSION NUMBER: 0001127602-20-029315 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201116 FILED AS OF DATE: 20201117 DATE AS OF CHANGE: 20201117 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Zaks Tal Zvi CENTRAL INDEX KEY: 0001690927 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38753 FILM NUMBER: 201321840 MAIL ADDRESS: STREET 1: 122 BELLEVUE STREET CITY: NEWTON STATE: MA ZIP: 02458 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2020-11-16 0001682852 Moderna, Inc. MRNA 0001690927 Zaks Tal Zvi C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 1 Chief Medical Officer Common Stock 2020-11-16 4 M 0 5000 12.21 A 5000 D Common Stock 2020-11-16 4 M 0 10000 19.15 A 15000 D Common Stock 2020-11-16 4 S 0 700 94.42 D 14300 D Common Stock 2020-11-16 4 S 0 2895 95.36 D 11405 D Common Stock 2020-11-16 4 S 0 4179 96.44 D 7226 D Common Stock 2020-11-16 4 S 0 2623 97.45 D 4603 D Common Stock 2020-11-16 4 S 0 3003 98.34 D 1600 D Common Stock 2020-11-16 4 S 0 1600 99.20 D 0 D Stock Option (Right to Buy) 12.21 2020-11-16 4 M 0 5000 0 D 2027-10-03 Common Stock 5000 205824 D Stock Option (Right to Buy) 19.15 2020-11-16 4 M 0 10000 0 D 2026-08-10 Common Stock 10000 44790 D The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.81 to $94.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $94.85 to $95.80. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $95.89 to $96.89. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $96.91 to $97.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.92 to $98.92. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $98.94 to $99.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). This option is fully vested and exercisable. /s/ Lori Henderson, as Attorney-in-Fact 2020-11-17